Benaroya Research Institute Team

Benaroya Research Institute (BRI) is one of twenty-two type 1 diabetes TrialNet International Clinical Centers at the forefront of type 1 diabetes research. Led by Carla Greenbaum, MD, the TrialNet team at BRI is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis.

Our Team

Portrait photo

Carla Greenbaum, MD

Director, Diabetes Clinical Research Program, TrialNet Chair

Dr. Greenbaum joined the Benaroya Research Institute (BRI) in 2000, where she is a Member and serves as Director of the Diabetes Research Program and the BRI Clinical Research Center. Dr. Greenbaum serves on the Board of Directors for BRI and is a member of the BRI Institutional Review Board, which provides oversight for clinical studies. She currently serves as Chair of Type 1 Diabetes TrialNet

Portrait photo

Sandra Lord, MD

Bao Ng, DNP

Portrait photo

Dana VanBuecken, ARNP-BC

Anna Barash

Portrait photo

Corinna Tordillos

Kim Varner

Portrait photo

Nancy Wickstrom

Katie Bennett

Rishab Kotak

"We want to thank every person who has taken part of research over the past 20 years. Because of their participation, we can now identify the disease in earlier stages, long before symptoms appear. The next step is to find a way to stop the disease from progressing and prevent symptomatic type 1 diabetes." Carla Greenbaum,  MD

Regional Affiliates

Affiliates provide opportunities for people who do not live near a TrialNet Clinical Center. The affiliate sites listed below work with BRI to offer convenient participation in our research programs

Oregon Health Sciences University
3181 SW Sam Jackson Park Rd, OP05-DC , Portland, 97239 United States
Childrens Hospital & Regional Medical Center
4800 Sand Point Way NE , Seattle, 98105 United States
St. Lukes Humphreys Diabetes Center
1226 W. River St. , Boise, 83702 United States
Kadlec Medical Center Diabetes Learning Center
888 Swift Blvd , Richland, 99352 United States
Sacred Heart Medical Center
105 W. 8th Ave. , Spokane, 99204 United States
Billings Clinic Diabetes Center
2800 Tenth Avenue North , Billings, 59107 United States
Rocky Mountain Diabetes and Osteoporosis Center, PA
3910 Washington Parkway , Idaho Falls, 83404 United States
St. Vincent Healthcare Diabetes Center
2900 12th Ave North, STE 10 West , Billings, 59101 United States
Bend Memorial Clinic
1501 NE Medical Center Dr , Bend, 97701 United States

Research Studies

The following studies are actively recruiting participants. Please click on the study title to learn more. For those interested in participation, contact us for more information. 

Risk Screening Risk Screening for Relatives

If you have a relative with T1D, you may be eligible for risk screening that can detect the early stages of T1D years before symptoms appear. More

Monitoring Monitoring

Depending on your risk screening results, you may be eligible for monitoring. We’ll monitor you for disease progression and let you know if you become eligible for a study. More

Long Term Long-Term Follow-up

If you are diagnosed with T1D while participating in one of our prevention studies, we’re still here for you. You can continue to receive personal monitoring while helping us learn more. More

Prevention Study ATG Prevention Study (STOP-T1D)

TrialNet is testing a low dose of the immunotherapy drug anti-thymocyte globulin (ATG) to see if it can delay or prevent type 1 diabetes (T1D) in people ages 12 up to 35 who have a 50% risk of clinical diagnosis (Stage 3) within 2 years. Risk is defined by having two or more autoantibodies and abnormal blood sugar (Stage 2), plus at least one high-risk marker (based on test results). In an earlier TrialNet study for people newly diagnosed with T1D, low-dose ATG preserved insulin production and improved blood sugar control for 2 years. Details

Newly Diagnosed Rituximab-pvvr / Abatacept Newly Diagnosed Study (T1D RELAY)

TrialNet is testing rituximab-pvvr and abatacept in people (ages 8-45) who were newly diagnosed with type 1 diabetes (T1D) to learn if using both treatments, one after the other, maintains the body’s ability to make insulin. By adding abatacept after rituximab-pvvr, researchers predict more people will experience prolonged beta cell function during and possibly after treatment. Details

Newly Diagnosed JAK Inhibitors Newly Diagnosed Study (JAKPOT T1D)

TrialNet researchers are testing two different treatments – abrocitinib and ritlecitinib – to see if either or both can preserve insulin production in people (ages 12-35) newly diagnosed with type 1 diabetes (Stage 3 T1D). Abrocitinib and ritlecitinib are in a new class of autoimmune treatments called Janus kinase (JAK) inhibitors. Details

#T1DFamily Spotlight

Meet some of our TrialNet #T1DFamily members to learn what it’s like to participate in a TrialNet clinical research study.